Tumor Inflammation Signature (TIS) (RUO)

Helping Your Research

NanoString’s Tumor Inflammation Signature (TIS) (RUO) measures a peripherally suppressed adaptive immune response and helps distinguish immune “hot” from “cold” tumors. The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors. The Tumor Inflammation Signature includes 4 areas of immune biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.

When used with the nCounter® platform, the Tumor Inflammation Signature has proven performance with RNA extracted from FFPE samples. The Tumor Inflammation Signature can be purchased in many different product formats including Custom CodeSet and it is included in select prebuilt panels (PanCancer IO 360™ Panel, Breast Cancer 360™ Panel, Tumor Signaling 360™ Panel, Immune Exhaustion Panel, and the Autoimmune Profiling Panel). The Tumor Inflammation Signature can also be added as a Plus Product spike-in to any panel or Custom CodeSet.

The Tumor Inflammation Signature Assay At Work

The TIS Signature
Product Specifications
Catalog Information
The TIS Data Analysis Report
The TIS Signature

The TIS Signature

The Tumor Inflammation Signature was developed and trained in collaboration with Merck using data from different pembrolizumab clinical studies. Signature development started with a small pilot of 19 melanoma patients and the gene expression profiles (GEP) were ultimately defined using data from 220 patients with 9 cancers. The predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The Tumor Inflammation Signature correlates response to single agent Pembrolizumab independent of tumor cell of origin.1Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).

Please visit our TIS GEP: Use Cases in Sample Stratification, Assessment of Treatment Effect, and as a Component of a Multivariate Biomarker blog for more detailed information on TIS.

Composed of 18 different genes, TIS is a gene expression profile that covers 4 areas of biology – T Cell/NK cells, antigen presenting cells, IFNg biology, and T Cell exhaustion.
Product Specifications

Product Specifications

Catalog Information

Catalog Information

The TIS Data Analysis Report

The TIS Data Analysis Report

There are several options for obtaining Tumor Inflammation Signature scores. Data generated using the PanCancer IO 360™ Panel or the Breast Cancer 360™ Panel can be used to generate a 360 Data Analysis Report. Individual TIS signature reports can be generated for other panel data containing the signature. You can access Tumor Inflammation Signature analysis using NanoString’s Data Analysis Services or several Contract Research Organizations.

Single Sample Analysis

Signature scores are shown for the selected sample, with TIS in the center. Scores range from approximately 0-10; for most scores, a value of 5 is average. Each unit increase in score corresponds to a doubling of the biological process it measures. Color denotes each signature’s biological function.

Publications & Posters

Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer

BACKGROUND: Tertiary Lymphoid Structures (TLS) correlate with positive outcomes in patients with NSCLC and the efficacy of immune checkpoint blockade (ICB) in cancer. The actin regulatory protein hMENA undergoes tissue-specific splicing, producing the epithelial hMENA(11a) linked to favorable prognosis in early NSCLC, and the mesenchymal hMENADeltav6 found in invasive cancer cells and pro-tumoral cancer-associated fibroblasts (CAFs).

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

BACKGROUND: HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance in part due to HER2 heterogeneity (HET) is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (T-DM1+P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR).

Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology

Posterior fossa type A (PF-EPN-A, PFA) ependymoma are aggressive tumors that mainly affect children and have a poor prognosis. Histopathology shows significant intratumoral heterogeneity, ranging from loose tissue to often sharply demarcated, extremely cell-dense tumor areas.

Request a Quote

Contact our helpful experts and we’ll be in touch soon.